Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes

References

• WhitingDRGuariguataLWeilCShawJIDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030Diabetes Res Clin Pract201194331132122079683
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBAmerican Diabetes Association (ADA)European Association for the Study of Diabetes (EASD)Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care20123561364137922517736
   PubMed Web of Science ®Google Scholar
• ReichardPNilssonBYRosenqvistUThe effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitusN Engl J Med199332953043098147960
   PubMed Web of Science ®Google Scholar
• [No authors listed]Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) GroupLancet199835291318378539742976
   PubMed Web of Science ®Google Scholar
• [No authors listed]Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) GroupLancet199835291318548659742977
   PubMed Web of Science ®Google Scholar
• [No authors listed]Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research GroupN Engl J Med2000342638138910666428
   PubMed Web of Science ®Google Scholar
• BaileyCJBlondeLDel PratoSLeiterLANestoRGlobal Partnership for Effective Diabetes ManagementWhat are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes ManagementDiab Vasc Dis Res20096428328720368223
   PubMed Web of Science ®Google Scholar
• RayKKSeshasaiSRWijesuriyaSEffect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trialsLancet200937396771765177219465231
   PubMed Web of Science ®Google Scholar
• YakubovichNGersteinHCSerious cardiovascular outcomes in diabetes: the role of hypoglycemiaCirculation2011123334234821263007
   PubMed Web of Science ®Google Scholar
• NathanDMClearyPABacklundJYDiabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research GroupIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetesN Engl J Med2005353252643265316371630
   PubMed Web of Science ®Google Scholar
• SkylerJSBergenstalRBonowROAmerican Diabetes AssociationAmerican College of Cardiology FoundationAmerican Heart AssociationIntensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart AssociationDiabetes Care200932118719219092168
   PubMed Web of Science ®Google Scholar
• SkylerJSBergenstalRBonowROAmerican Diabetes AssociationAmerican College of Cardiology FoundationAmerican Heart AssociationIntensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart AssociationCirculation2009119235135719095622
   PubMed Web of Science ®Google Scholar
• KongAPYangXLukASevere hypoglycemia identifies vulnerable patients with type 2 diabetes at risk for premature death and all-site cancer: the Hong Kong diabetes registryDiabetes Care20143741024103124513587
   PubMed Web of Science ®Google Scholar
• BudnitzDSLovegroveMCShehabNRichardsCLEmergency hospitalizations for adverse drug events in older AmericansN Engl J Med2011365212002201222111719
   PubMed Web of Science ®Google Scholar
• HolsteinAEgbertsEHRisk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetesExp Clin Endocrinol Diabetes2003111740541414614647
   PubMed Web of Science ®Google Scholar
• LeeseGPWangJBroomhallJDARTS/MEMO CollaborationFrequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource useDiabetes Care20032641176118012663593
   PubMed Web of Science ®Google Scholar
• BulsaraMKHolmanCDDavisEAJonesTWThe impact of a decade of changing treatment on rates of severe hypoglycemia in a population-based cohort of children with type 1 diabetesDiabetes Care200427102293229815451890
   PubMed Web of Science ®Google Scholar
• EvansMKhuntiKMamdaniMHealth-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countriesHealth Qual Life Outcomes2013119023731777
   PubMed Web of Science ®Google Scholar
• PeyrotMBarnettAHMeneghiniLFSchumm-DraegerPMInsulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy studyDiabet Med201229568268922313123
   PubMed Web of Science ®Google Scholar
• HirschIBBodeBCourregesJPInsulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trialDiabetes Care201235112174218122933438
   PubMed Web of Science ®Google Scholar
• BolliGBDi MarchiRDParkGDPrammingSKoivistoVAInsulin analogues and their potential in the management of diabetes mellitusDiabetologia199942101151116710525654
   PubMed Web of Science ®Google Scholar
• HirschIBInsulin analoguesN Engl J Med2005352217418315647580
   PubMed Web of Science ®Google Scholar
• CrastoWJarvisJKhuntiKDaviesMJNew insulins and new insulin regimens: a review of their role in improving glycaemic control in patients with diabetesPostgrad Med J200985100325726719520878
   PubMed Web of Science ®Google Scholar
• DeWittDEHirschIBOutpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific reviewJAMA2003289172254226412734137
   PubMed Web of Science ®Google Scholar
• RosenstockJDaileyGMassi-BenedettiMFritscheALinZSalzmanAReduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetesDiabetes Care200528495095515793205
   PubMed Web of Science ®Google Scholar
• GoughSCA review of human and analogue insulin trialsDiabetes Res Clin Pract200777111517112621
   PubMed Web of Science ®Google Scholar
• BeckerRHFrickADClinical pharmacokinetics and pharmacodynamics of insulin glulisineClin Pharmacokinet200847172018076215
   PubMed Web of Science ®Google Scholar
• HartmanIInsulin analogs: impact on treatment success, satisfaction, quality of life, and adherenceClin Med Res200862546718801953
   PubMedGoogle Scholar
• OwensDRBolliGBBeyond the era of NPH insulin – long-acting insulin analogs: chemistry, comparative pharmacology, and clinical applicationDiabetes Technol Ther200810533334918715209
   PubMed Web of Science ®Google Scholar
• EvansMSchumm-DraegerPMVoraJKingABA review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitationsDiabetes Obes Metab201113867768421410860
   PubMed Web of Science ®Google Scholar
• TibaldiJMEvolution of insulin development: focus on key parametersAdv Ther201229759061922843207
   PubMed Web of Science ®Google Scholar
• KalraSBaruahMPNiaziAKDegludec: a novel basal insulinRecent Pat Endocr Metab Immune Drug Discov201261182322280221
   PubMedGoogle Scholar
• European Medicines AgencyTresiba (insulin degludec): EU summary of product characteristics2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Product_Information/human/002498/WC500138940.pdfAccessed February 1, 2013
   Google Scholar
• JonassenIHavelundSHoeg-JensenTSteensgaardDBWahlundPORibelUDesign of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulinPharm Res20122982104211422485010
   PubMed Web of Science ®Google Scholar
• HeiseTHermanskiLNosekLFeldmanARasmussenSHaahrHInsulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetesDiabetes Obes Metab201214985986422594461
   PubMed Web of Science ®Google Scholar
• WangFSurhJKaurMInsulin degludec as an ultralong-acting basal insulin once a day: a systematic reviewDiabetes Metab Syndr Obes2012519120422826637
   PubMedGoogle Scholar
• Goldman-LevineJDPatelDKSchneeDMInsulin degludec: a novel basal insulin analogueAnn Pharmacother201347226927723386075
   PubMed Web of Science ®Google Scholar
• KeatingGMInsulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitusDrugs201373657559323620200
   PubMed Web of Science ®Google Scholar
• GoughSCHarrisSWooVDaviesMInsulin degludec: overview of a novel ultra long-acting basal insulinDiabetes Obes Metab201315430130923240573
   PubMed Web of Science ®Google Scholar
• BirkelandKIHomePDWendischUInsulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargineDiabetes Care201134366166521270174
   PubMed Web of Science ®Google Scholar
• HellerSBuseJFisherMBEGIN Basal-Bolus Type 1 Trial InvestigatorsInsulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trialLancet201237998251489149722521071
   PubMed Web of Science ®Google Scholar
• MathieuCHollanderPMiranda-PalmaBNN1250-3770 (BEGIN: Flex T1) Trial InvestigatorsEfficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extensionJ Clin Endocrinol Metab20139831154116223393185
   PubMed Web of Science ®Google Scholar
• BodeBWBuseJBFisherMBEGIN® Basal-Bolus Type 1 trial investigatorsInsulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trialDiabet Med201330111293129723710902
   PubMed Web of Science ®Google Scholar
• KoehlerGHellerSKorsatkoSInsulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover studyDiabetologia2014571404924057153
   PubMed Web of Science ®Google Scholar
• KorsatkoSDellerSMaderJKUltra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitusDrugs Aging2014311475324263619
   PubMed Web of Science ®Google Scholar
• BiesterTBlaesigSRemusKInsulin degludec’s ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetesPediatr Diabetes2014151273324467565
   PubMed Web of Science ®Google Scholar
• DaviesMJGrossJLOnoYBEGIN BB T1 study groupEfficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trialDiabetes Obes Metab Epub201447
   Web of Science ®Google Scholar
• ZinmanBFulcherGRaoPVInsulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trialLancet2011377976992493121396703
   PubMed Web of Science ®Google Scholar
• GarberAJKingABDel PratoSNN1250-3582 (BEGIN BB T2D) Trial InvestigatorsInsulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trialLancet201237998251498150722521072
   PubMed Web of Science ®Google Scholar
• HeiseTNosekLBøttcherSGHastrupHHaahrHUltra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetesDiabetes Obes Metab2012141094495022726241
   PubMed Web of Science ®Google Scholar
• ZinmanBPhilis-TsimikasACariouBNN1250-3579 (BEGIN Once Long) Trial InvestigatorsInsulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)Diabetes Care201235122464247123043166
   PubMed Web of Science ®Google Scholar
• MeneghiniLAtkinSLGoughSCNN1250-3668 (BEGIN FLEX) Trial InvestigatorsThe efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetesDiabetes Care201336485886423340894
   PubMed Web of Science ®Google Scholar
• Philis-TsimikasADel PratoSSatmanIEffect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agentsDiabetes Obes Metab201315876076623577643
   PubMed Web of Science ®Google Scholar
• GoughSCBhargavaAJainRMersebachHRasmussenSBergenstalRMLow-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trialDiabetes Care20133692536254223715753
   PubMed Web of Science ®Google Scholar
• Philis-TsimikasABrodMNiemeyerMOcampo FranciscoAMRothmanJInsulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use)Adv Ther201330660762223812875
   PubMed Web of Science ®Google Scholar
• RodbardHWCariouBZinmanBBEGIN Once Long trial investigatorsComparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trialDiabet Med201330111298130423952326
   PubMed Web of Science ®Google Scholar
• ZinmanBDeVriesJHBodeBNN1250-3724 (BEGIN:EASY AM) and NN1250-3718 (BEGIN:EASY PM) Trial InvestigatorsEfficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trialsLancet Diabetes Endocrinol20131212313124622318
   PubMed Web of Science ®Google Scholar
• KissIAroldGRoepstorffCBøttcherSGKlimSHaahrHInsulin degludec: pharmacokinetics in patients with renal impairmentClin Pharmacokinet201453217518324163264
   PubMed Web of Science ®Google Scholar
• KupčováVAroldGRoepstorffCHøjbjerreMKlimSHaahrHInsulin degludec: pharmacokinetic properties in subjects with hepatic impairmentClin Drug Investig2014342127133
   PubMed Web of Science ®Google Scholar
• MathieuCRodbardHWCariouBBEGIN: VICTOZA ADD-ON (NN1250-3948) study groupA comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)Diabetes Obes Metab Epub1202014
   Web of Science ®Google Scholar
• RodbardHWCariouBZinmanBHealth status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetesDiabetes Obes Metab Epub242014
   Web of Science ®Google Scholar
• HompeschMMorrowLWatkinsERoepstorffCThomsenHFHaahrHPharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitusClin Ther201436450751524508419
   PubMed Web of Science ®Google Scholar
• BodeBWChaykinLBSussmanAMEfficacy and Safety of Insulin Degludec 200 U/ML and Insulin Degludec 100 U/ML in Patients with Type 2 Diabetes (Begin: Compare)Endocr Pract Epub211201411624518180
   PubMedGoogle Scholar
• European Medicines AgencyRyzodeg (insulin degludec/insulin aspart): EU summary of product characteristics2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Product_Information/human/002499/WC500139011.pdfAccessed February 1, 2013
   Google Scholar
• MaZParknerTChristiansenJSLaursenTIDegAsp: a novel soluble insulin analogs combinationExpert Opin Biol Ther201212111533154022946603
   PubMed Web of Science ®Google Scholar
• HellerSKurtzhalsPVergeDLindholmAInsulin aspart: promising early results borne out in clinical practiceExpert Opin Pharmacother20023218319511829732
   PubMedGoogle Scholar
• ØsterbergOErichsenLIngwersenSHPlumAPoulsenHEViciniPPharmacokinetic and pharmacodynamic properties of insulin aspart and human insulinJ Pharmacokinet Pharmacodyn200330322123514571692
   PubMed Web of Science ®Google Scholar
• HomePDThe pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequencesDiabetes Obes Metab201214978078822321739
   PubMed Web of Science ®Google Scholar
• ReynoldsNAWagstaffAJInsulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitusDrugs200464171957197415329046
   PubMed Web of Science ®Google Scholar
• HellerSMcCanceDRMoghissiENazeriAKordonouriODiversity in diabetes: the role of insulin aspartDiabetes Metab Res Rev2012281506121695769
   PubMed Web of Science ®Google Scholar
• RendellMInsulin degludec: a long-acting modern insulin analogue with a predictable pharmacokinetic/pharmacodynamic profileDrugs Today (Barc)201349638739723807942
   PubMed Web of Science ®Google Scholar
• PoonKKingABGlargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogsDrug Healthc Patient Saf2010221322321701633
   PubMedGoogle Scholar
• European Medicines AgencyEPAR summary for the public: Ryzodeg (insulin degludec/insulin aspart) Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002499/WC500139014.pdfAccessed July 1, 2014
   Google Scholar
• HeiseTTackCJCuddihyRA new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trialDiabetes Care201134366967421285389
   PubMed Web of Science ®Google Scholar
• NiskanenLLeiterLAFranekEComparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trialEur J Endocrinol2012167228729422660026
   PubMed Web of Science ®Google Scholar
• LieblADavidsonJMersebachHDykielPTackCJHeiseTA novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trialJ Diabetes Sci Technol2013751328133624124961
   PubMedGoogle Scholar
• OnishiYOnoYRabølREndahlLNakamuraSSuperior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trialDiabetes Obes Metab201315982683223557077
   PubMed Web of Science ®Google Scholar
• BonoraEPostprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectivesInt J Clin Pract Suppl200212951112166607
   PubMedGoogle Scholar